Equity Analysis /
United States of America

US : CymaBay Therapeutics, Inc. - CBAY | 4Q21 Update: Phase 3 Enrollment Seemingly Inflected as Expected

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    25 March 2022
    Published by